Please use this identifier to cite or link to this item:
Title: Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Austin Authors: Dubois, Bruno;Hampel, Harald;Feldman, Howard H;Scheltens, Philip;Aisen, Paul;Andrieu, Sandrine;Bakardjian, Hovagim;Benali, Habib;Bertram, Lars;Blennow, Kaj;Broich, Karl;Cavedo, Enrica;Crutch, Sebastian;Dartigues, Jean-François;Duyckaerts, Charles;Epelbaum, Stéphane;Frisoni, Giovanni B;Gauthier, Serge;Genthon, Remy;Gouw, Alida A;Habert, Marie-Odile;Holtzman, David M;Kivipelto, Miia;Lista, Simone;Molinuevo, José-Luis;O'Bryant, Sid E;Rabinovici, Gil D;Rowe, Christopher C ;Salloway, Stephen;Schneider, Lon S;Sperling, Reisa;Teichmann, Marc;Carrillo, Maria C;Cummings, Jeffrey;Jack, Cliff R
Affiliation: IRCCS Fatebenefratelli, Brescia, Italy
Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France
University Hospitals and University of Geneva, Geneva, Switzerland
University of British Columbia, Canada
Department of Neurology and Alzheimer Center, VU University Medical Center and Neuroscience Campus, Amsterdam, The Netherlands
University of Southern California San Diego, CA, USA
UMR1027, INSERM, Université Toulouse III, Toulouse University Hospital, France
IHU-A-ICM-Institut des Neurosciences translationnelles de Paris, Paris, France
INSERM U1146-CNRS UMR 7371-UPMC UM CR2, Site Pitié-Salpêtrière, Paris, France
Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Integrative and Experimental Genomics, University of Lübeck, Lübeck, Germany
School of Public Health, Faculty of Medicine, Imperial College London, London, UK
Clinical Neurochemistry Lab, Department of Neuroscience and Physiology, University of Gothenburg, Mölndal Hospital, Sahlgrenska University Hospital, Mölndal, Sweden
Federal Institute for Drugs and Medical Devices, Bonn, Germany
Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK
INSERM U 1219, Université de Bordeaux, France
University Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, Alzheimer-Prion Team Institut du Cerveau et de la Moelle (ICM), Paris, France
McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada
Fondation pour la Recherche sur Alzheimer, Hôpital Pitié-Salpêtrière, Paris, France
Department of Clinical Neurophysiology/MEG Center, VU University Medical Center, Amsterdam
Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Paris, France
AP-HP, Hôpital Pitié-Salpêtrière, Département de Médecine Nucléaire, Paris, France
Department of Neurology, Washington University, Hope Center for Neurological Disorders, St. Louis, MO, USA
Department of Neurology, Washington University, Knight Alzheimer's Disease Research Center, St. Louis, MO, USA
Center for Alzheimer Research, Karolinska Institutet, Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden
Institute of Clinical Medicine/ Neurology, University of Eastern Finland, Kuopio, Finland
AXA Research Fund & UPMC Chair, Paris, France
Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center, TX, USA
Memory & Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA
Department of Molecular Imaging, Austin Health, University of Melbourne, Australia
Memory and Aging Program, Butler Hospital, Alpert Medical School of Brown University, USA
Department of Neurology, Alpert Medical School of Brown University, USA
Department of Psychiatry, Alpert Medical School of Brown University, USA
Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
Harvard Medical School, Memory Disorders Unit, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, USA
Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
The Alzheimer's Association Division of Medical & Scientific Relations, Chicago, USA
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
Department of Radiology, Mayo Clinic, Rochester MN, USA
Issue Date: Mar-2016
Publication information: Alzheimer's & dementia : the journal of the Alzheimer's Association 2016; 12(3): 292-323
Abstract: During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
DOI: 10.1016/j.jalz.2016.02.002
ORCID: 0000-0003-3910-2453
PubMed URL: 27012484
Type: Journal Article
Subjects: Alzheimer's disease
Amyloid PET
Blood biomarkers
CSF biomarkers
Diagnostic criteria
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.